Multidisciplinary Association for Psychedelic Studies   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Santa Cruz CA United States (1986)

Organization Overview

First Clinical Trial
2004
NCT00090064
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Multidisciplinary Association for Psychedelic Studies

Active Ingredients

Drugs in Phase 3 Trials (1)

3,4-Methyl​enedioxy​methamphetamine (32 trials)

Drugs in Phase 2 Trials (5)

cannabis (1 trial)

ibogaine (1 trial)

lactose (2 trials)

lysergic acid diethylamide (1 trial)

psilocybin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Anorexia Nervosa (Phase 2)

Anxiety Disorders (Phase 2)

Autistic Disorder (Phase 2)

Binge-Eating Disorder (Phase 2)

Bulimia (Phase 2)

Combat Disorders (Phase 2)

Disease (Phase 2)

Feeding and Eating Disorders (Phase 2)

Liver Diseases (Phase 1)

Marijuana Abuse (Phase 2)

Melanoma (Phase 2)

Opioid-Related Disorders (Phase 2)

Stress Disorders, Post-Traumatic (Phase 3)

Stress Disorders, Traumatic (Phase 3)

Substance-Related Disorders (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 36
  • # of Trial APIs: 6